BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zeifman RJ, Singhal N, Dos Santos RG, Sanches RF, de Lima Osório F, Hallak JEC, Weissman CR. Rapid and sustained decreases in suicidality following a single dose of ayahuasca among individuals with recurrent major depressive disorder: results from an open-label trial. Psychopharmacology (Berl) 2021;238:453-9. [PMID: 33118052 DOI: 10.1007/s00213-020-05692-9] [Cited by in Crossref: 8] [Cited by in F6Publishing: 22] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Rosenblat JD, Husain MI, Lee Y, McIntyre RS, Mansur RB, Castle D, Offman H, Parikh SV, Frey BN, Schaffer A, Greenwaym KT, Garel N, Beaulieu S, Kennedy SH, Lam RW, Milev R, Ravindran AV, Tourjman V, Ameringen MV, Yatham LN, Taylor V. The Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force Report: Serotonergic Psychedelic Treatments for Major Depressive Disorder. Can J Psychiatry 2022;:7067437221111371. [PMID: 35975555 DOI: 10.1177/07067437221111371] [Reference Citation Analysis]
2 Brennan W, Belser AB. Models of Psychedelic-Assisted Psychotherapy: A Contemporary Assessment and an Introduction to EMBARK, a Transdiagnostic, Trans-Drug Model. Front Psychol 2022;13:866018. [PMID: 35719571 DOI: 10.3389/fpsyg.2022.866018] [Reference Citation Analysis]
3 Kohek M, Ona G, van Elk M, Dos Santos RG, Hallak JEC, Alcázar-córcoles MÁ, Bouso JC. Ayahuasca and Public Health II: Health Status in a Large Sample of Ayahuasca-Ceremony Participants in the Netherlands. Journal of Psychoactive Drugs. [DOI: 10.1080/02791072.2022.2077155] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Daldegan-Bueno D, Révész D, Morais PR, Barbosa PCR, Maia LO. Psychosocial and Drug Use Assessment of Regular vs. Non-Regular Ayahuasca Users in a Brazilian Sample: a Web-Based Survey. Subst Use Misuse 2022;57:1072-81. [PMID: 35466853 DOI: 10.1080/10826084.2022.2063896] [Reference Citation Analysis]
5 James E, Keppler J, L Robertshaw T, Sessa B. N,N-dimethyltryptamine and Amazonian ayahuasca plant medicine. Hum Psychopharmacol 2022;37:e2835. [PMID: 35175662 DOI: 10.1002/hup.2835] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
6 Rodríguez L, López A, Moyna G, Seoane GA, Davyt D, Vázquez Á, Hernández G, Carrera I. New Insights into the Chemical Composition of Ayahuasca. ACS Omega 2022;7:12307-17. [PMID: 35449956 DOI: 10.1021/acsomega.2c00795] [Reference Citation Analysis]
7 van den Berg M, Magaraggia I, Schreiber R, Hillhouse TM, Porter JH. How to account for hallucinations in the interpretation of the antidepressant effects of psychedelics: a translational framework. Psychopharmacology (Berl) 2022. [PMID: 35348806 DOI: 10.1007/s00213-022-06106-8] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Lawrence DW. Heart rate (HR) and heart rate variability (HRV) response to inhaled N, N-dimethyltryptamine (N, N-DMT): A case report. JPS 2022. [DOI: 10.1556/2054.2022.00178] [Reference Citation Analysis]
9 Bender D, Hellerstein DJ. Assessing the risk–benefit profile of classical psychedelics: a clinical review of second-wave psychedelic research. Psychopharmacology. [DOI: 10.1007/s00213-021-06049-6] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 8.0] [Reference Citation Analysis]
10 Jones GM, Nock MK. Lifetime use of MDMA/ecstasy and psilocybin is associated with reduced odds of major depressive episodes. J Psychopharmacol 2022;:2698811211066714. [PMID: 34983261 DOI: 10.1177/02698811211066714] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 8.0] [Reference Citation Analysis]
11 Kelly JR, Gillan CM, Prenderville J, Kelly C, Harkin A, Clarke G, O'Keane V. Psychedelic Therapy's Transdiagnostic Effects: A Research Domain Criteria (RDoC) Perspective. Front Psychiatry 2021;12:800072. [PMID: 34975593 DOI: 10.3389/fpsyt.2021.800072] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
12 Berlowitz I, O'Shaughnessy DM, Heinrich M, Wolf U, Maake C, Martin-Soelch C. Teacher plants - Indigenous Peruvian-Amazonian dietary practices as a method for using psychoactives. J Ethnopharmacol 2021;286:114910. [PMID: 34933085 DOI: 10.1016/j.jep.2021.114910] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
13 Strumila R, Nobile B, Korsakova L, Lengvenyte A, Olie E, Lopez-Castroman J, Guillaume S, Courtet P. Psilocybin, a Naturally Occurring Indoleamine Compound, Could Be Useful to Prevent Suicidal Behaviors. Pharmaceuticals (Basel) 2021;14:1213. [PMID: 34959614 DOI: 10.3390/ph14121213] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 5.0] [Reference Citation Analysis]
14 Leger RF, Unterwald EM. Assessing the effects of methodological differences on outcomes in the use of psychedelics in the treatment of anxiety and depressive disorders: A systematic review and meta-analysis. J Psychopharmacol 2021;:2698811211044688. [PMID: 34519567 DOI: 10.1177/02698811211044688] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
15 Więckiewicz G, Stokłosa I, Piegza M, Gorczyca P, Pudlo R. Lysergic Acid Diethylamide, Psilocybin and Dimethyltryptamine in Depression Treatment: A Systematic Review. Pharmaceuticals (Basel) 2021;14:793. [PMID: 34451890 DOI: 10.3390/ph14080793] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
16 Palamar JJ, Le A. Media coverage about medical benefits of MDMA and ketamine affects perceived likelihood of engaging in recreational use. Addiction Research & Theory. [DOI: 10.1080/16066359.2021.1940972] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
17 Ruffell SGD, Netzband N, Tsang W, Davies M, Butler M, Rucker JJH, Tófoli LF, Dempster EL, Young AH, Morgan CJA. Ceremonial Ayahuasca in Amazonian Retreats-Mental Health and Epigenetic Outcomes From a Six-Month Naturalistic Study. Front Psychiatry 2021;12:687615. [PMID: 34177670 DOI: 10.3389/fpsyt.2021.687615] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
18 Ross S, Agin-Liebes G, Lo S, Zeifman RJ, Ghazal L, Benville J, Franco Corso S, Bjerre Real C, Guss J, Bossis A, Mennenga SE. Acute and Sustained Reductions in Loss of Meaning and Suicidal Ideation Following Psilocybin-Assisted Psychotherapy for Psychiatric and Existential Distress in Life-Threatening Cancer. ACS Pharmacol Transl Sci 2021;4:553-62. [PMID: 33860185 DOI: 10.1021/acsptsci.1c00020] [Cited by in Crossref: 3] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
19 Zeifman RJ, Singhal N, Breslow L, Weissman CR. On the Relationship between Classic Psychedelics and Suicidality: A Systematic Review. ACS Pharmacol Transl Sci 2021;4:436-51. [PMID: 33860173 DOI: 10.1021/acsptsci.1c00024] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
20 Dos Santos RG, Bouso JC, Rocha JM, Rossi GN, Hallak JE. The Use of Classic Hallucinogens/Psychedelics in a Therapeutic Context: Healthcare Policy Opportunities and Challenges. Risk Manag Healthc Policy 2021;14:901-10. [PMID: 33707976 DOI: 10.2147/RMHP.S300656] [Cited by in Crossref: 3] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
21 Weissman CR, Hadas I, Yu D, Jones B, Kong D, Mulsant BH, Blumberger DM, Daskalakis ZJ. Predictors of change in suicidal ideation across treatment phases of major depressive disorder: analysis of the STAR*D data. Neuropsychopharmacology 2021;46:1293-9. [PMID: 33479508 DOI: 10.1038/s41386-020-00953-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
22 Inserra A, De Gregorio D, Gobbi G. Psychedelics in Psychiatry: Neuroplastic, Immunomodulatory, and Neurotransmitter Mechanisms. Pharmacol Rev 2021;73:202-77. [PMID: 33328244 DOI: 10.1124/pharmrev.120.000056] [Cited by in Crossref: 9] [Cited by in F6Publishing: 33] [Article Influence: 4.5] [Reference Citation Analysis]